Fluogen; Fluzone Mechanism of Action Promotes immunity to influenza virus by inducing specific antibody production.

E ach year the formulation is standardized according to the U.S. Public Health Ser vice. Preparations from previous seasons must not be used. Dosage Children greater than or equal to 9 years and Adults: 0.5 mL each year of approp riate vaccine for the year, one dose is all that is necessary; administer in lat e fall to allow maximum titers to develop by peak epidemic periods usually occur ring in early December Administration Administer in anterolateral aspect of thigh for children; for adults, in deltoid muscle Use Provide active immunity to influenza virus strains contained in the vaccine; for high-risk persons, previous year vaccines should not be used to prevent present year influenza Persons greater than or equal to 65 years of age Residents of nursing homes and other chronic-care facilities that house persons of any age with chronic medical conditions Adults and children with chronic disorders of the pulmonary or cardiovascular sy stems, including children with asthma Adults and children who have required regular medical follow-up or hospitalizati on during the preceding year because of chronic metabolic diseases (including di abetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (i ncluding immunosuppression caused by medications) Contraindications Persons with allergy history to eggs or egg products, chicken, chicken feathers or chicken dander, hypersensitivity to thimerosal, influenza virus vaccine or an y component, presence of acute respiratory disease or other active infections or illnesses, delay immunization in a patient with an active neurological disorder Adverse Reactions All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-8 22-7967. Central nervous system: Fever, malaise Local: Tenderness, redness, or induration at the site of injection (<33%) <1%: Guillain-Barr syndrome, fever, urticaria, angioedema, myalgia, asthma, anaph ylactoid reactions (most likely to residual egg protein), allergic reactions Nursing Implications Inspect for particulate matter and discoloration prior to administration; for I. M. administration only